Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Operationalization drift in the construct of impulsivity: relevance to animal models of addiction.

Translational psychiatry·2026
Same author

Lost in translation-what is translational neuroscience research?

Brain communications·2026
Same author

A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.

Science (New York, N.Y.)·2026
Same author

Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.

Brain : a journal of neurology·2026
Same author

Celebrating the founding editor of <i>Brain Communications</i>: Tara Spires-Jones.

Brain communications·2026
Same author

Human Blood IgA<sup>+</sup> Memory B Cells Differ From IgG<sup>+</sup> B Cells by Expressing Gut-Homing and Regulatory Markers.

European journal of immunology·2026
Same journal

Functional connectivity of orbitofrontal cortex predicts cocaine relapse: Protective and risk circuits, individual differences, and neuromodulation implications.

Biological psychiatry·2026
Same journal

Takeda G protein-coupled receptor 5 orchestrates anxiolysis by enhancing anterior paraventricular thalamic nucleus glutamatergic neuronal activity to engage distinct downstream circuits.

Biological psychiatry·2026
Same journal

Neuroimaging of Heterogeneity in Neuropsychiatric Disorders: Toward Disease Progression Modeling.

Biological psychiatry·2026
Same journal

Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial.

Biological psychiatry·2026
Same journal

Remembering Jon-Kar Zubieta, M.D., Ph.D.

Biological psychiatry·2026
Same journal

Kappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [<sup>11</sup>C]EKAP PET imaging.

Biological psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K

Atomoxetine decreases vulnerability to develop compulsivity in high impulsive rats.

Solène Ansquer1, Aude Belin-Rauscent2, Emilie Dugast3

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; Service de Neurologie de l'Hôpital de Poitiers, Poitiers, France.

Biological Psychiatry
|November 21, 2013
PubMed
Summary
This summary is machine-generated.

High impulsivity traits in rats predict compulsive behaviors. Atomoxetine treatment reduced impulsivity and prevented compulsivity development, suggesting potential therapeutic use for obsessive-compulsive spectrum disorders.

Keywords:
AtomoxetineTourette’s syndromecompulsivityfive-choice serial reaction time taskimpulsivity traitobsessive-compulsive spectrum disordersschedule-induced polydipsia

More Related Videos

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

18.6K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K

Related Experiment Videos

Last Updated: May 5, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

18.6K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K

Area of Science:

  • Neuroscience
  • Behavioral Science
  • Psychiatry

Background:

  • Obsessive-compulsive spectrum disorders (OCSDs) have poorly understood causes, hindering effective treatments.
  • Impulse-control deficits are linked to increased compulsivity in OCSDs.
  • Impulsivity may be a shared vulnerability factor across various compulsive disorders.

Purpose of the Study:

  • To investigate the relationship between impulsivity and the development of compulsive behavior in a rat model.
  • To explore the potential of atomoxetine in modulating impulsivity and compulsivity.

Main Methods:

  • Assessed trait impulsivity using the five-choice serial reaction time task in rats.
  • Measured compulsive behavior using a schedule-induced polydipsia procedure.
  • Administered atomoxetine, a noradrenergic reuptake inhibitor, to evaluate its effects.

Main Results:

  • High trait impulsivity predicted a greater propensity to develop compulsive behavior.
  • The relationship between impulsivity and compulsivity was nonlinear.
  • Atomoxetine treatment decreased impulsivity and prevented the development of compulsivity in high-impulsive rats.

Conclusions:

  • Impulsivity and compulsivity exhibit a reciprocal influence in compulsive disorders.
  • Atomoxetine shows promise as a treatment for OCSDs, particularly in individuals with high impulsivity.